A lthough significant progress has occurred in the past 20 years regarding our understanding of Alzheimer disease pathogenesis, we have yet to identify diseasemodifying therapeutics capable of substantially altering the clinical course of this prevalent neurodegenerative disease. In this short review, we discuss 2 approaches that are currently being tested clinically (␥-secretase inhibition and ␥-secretase modulation) and emphasize the significant differences between these 2 therapeutic approaches. We also discuss certain genetic-and biomarker-based translational and clinical trial paradigms that may assist in developing a useful therapeutic agent.
Genetic models have long been used to devise and evaluate rational approaches to the treatment of high-prevalence diseases such as coronary artery disease and stroke. One of the most notable examples was in the pioneering studies of Mabuchi et al 1 reporting the highly beneficial effects of a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, compactin, in patients with familial hypercholesterolemia. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase is the enzyme that catalyzes the conversion of 3-hydroxy-3-methylglutarylcoenzyme A to mevalonate, the ratelimiting step in cholesterol synthesis. This historic study involving 7 patients with a mutation in the low-density lipoprotein receptor gene (LDLR) reported the successful lowering of low-density lipoprotein cholesterol levels without changing or even slightly increasing high-density lipoprotein cholesterol levels. That small proofof-concept clinical pharmacodynamic study eventually paved the way to the subsequent development of a related class of molecules known as the synthetic statins (eg, fluvastatin, atorvastatin, and rosuvastatin), and according to the American Heart Association (http://www.heart.org), statins can safely elicit a selective lowering of low-density lipoprotein cholesterol levels and long-term administration of statins can reduce the incidence of coronary artery disease and stroke by more than 25% to 30%.
Alzheimer disease (AD) affects approximately 1 in 8 Americans aged 65 years or older. Unfortunately, unlike coronary artery disease and stroke, there are currently no effective disease-modifying or preventive therapies available. However, more than 200 different mutations have been identified in 3 genes associated with an autosomal dominant form of AD, referred to as early-onset familial Alzheimer disease (EOFAD). It is an aggressive form of AD that has served as a template for many of the cellular and transgenic animal models being used to study the pathogenesis of AD and is relevant to the more common late-onset AD. 2 The 3 genes causally implicated in EOFAD, which typically affects carriers before age 65 years and sometimes as early as the third or fourth decades, are APP (amyloid precursor protein), PSEN1 (presenilin 1), and PSEN2 (presenilin 2). The presenilin genes encode 2 highly homologous proteins that can independently assemble along with 3 other membrane-associated pro-teins, namely, nicastrin, anterior pharynx defective 1, and presenilin enhancer 2 (Pen-2), into a large membrane-bound enzymatic complex (Figure 1 ) that plays a key role in metabolizing a large number of type 1 membrane proteins, including APP. 2 The rationale for targeting this enzymatic complex, referred to as ␥-secretase, as a therapeutic approach for AD stems from the fact that ␥-secretase performs the terminal series of proteolytic cleavages that generate and release extracellularly a number of peptides known collectively as ␤-amyloid (A␤). 2 Most secreted A␤ peptides range in size from approximately 34 to 42 amino acids (Figure 1) . One of these, A␤42 (42 amino acids long), is the major peptide found in neuritic plaques and diffuse amyloid deposits, neuropathological lesions found in abundance in the brains of patients with AD at autopsy. In EOFAD, these and perhaps others that develop further downstream (eg, neurofibrillary tangles, another major neuropathological hallmark of AD) arise owing to a change in the ratio of cerebral levels of A␤42 relative to the next longest A␤ peptide, A␤40 (which is by far the most abundant of all secreted A␤ peptides), increasing the A␤42/A␤40 ratio approximately 2-fold. 2 Initial therapeutic interventions targeting ␥-secretase focused on curbing total A␤ peptide production by directly inhibiting ␥-secretase activity through a class of compounds referred to as ␥-secretase inhibitors (GSIs). 3 The GSIs attenuate the production of all major A␤ peptide variants (eg, A␤42, A␤40, A␤39, A␤38, and A␤37) equivalently (Figure 2 ) and inhibit the generation of an APP intracellular domain and the Notch-1 receptor intracellular domain. Notch is a key substrate of ␥-secretase, and the Notch-1 receptor intracellular domain peptide plays an important role in the differentiation of multiple cell types. 4 The GSIs also cause accumulation of the ␥-secretase substrate C99 (the C-terminal fragment of APP generated by the A␤-cleaving enzyme BACE 1) as well as C-terminal fragments from a number of other type 1 membrane proteins believed to be degraded by ␥-secretase. 5 Eli Lilly and Co recently reported (http://www.lilly .com) that in 2 phase 3 clinical trials involving more than 2600 mildly to moderately affected patients with probable AD, the GSI semagacestat failed to slow disease progression and led to worsened cognition and performance of activities of daily living. In addition, semagacestat was associated with an increased risk of skin cancer. The explanation for these disappointing clinical outcomes is currently unknown but may be mechanistically related to inhibiting the ␥-secretase enzyme complex and attenuating the processing of 1 or more of its substrates including the Cterminal fragments of APP, Notch-1, and possibly other substrates. 5 Interestingly, the vast majority of EOFAD-linked mutations do not correlate with an overall increase in ␥-secretase activity, nor do they appear to increase total A␤ peptide levels. Instead, most appear to cause a 2-fold increase in the ratio of A␤42/ A␤40 ( Figure 2 ). This increased A␤42/A␤40 ratio is a highly reproducible biochemical phenotype (in vitro and in vivo) for the predominant effect of the more than 200 EOFAD-linked genetic mutations, including a number of mutations in APP (those proximal to the ␥-secretase cleavage site in the APP protein), all of those in PSEN2, and most of the large number of mutations in PSEN1. 2 Therefore, a therapeutic rationale based on this EOFAD genetics model would entail modulating ␥-secretase activity (decreasing the A␤42/A␤40 ratio), not inhibiting this important enzyme complex. The feasibility of this more selective EOFAD geneticsbased approach was first identified using a series of nonsteroidal antiinflammatory drug (NSAID)-like compounds, eg, ibuprofen and sulindac sulfide. 6 However, the NSAID-like compounds lack potency (Ն50- 100µM in vitro half-maximal inhibitory concentrations for selective lowering of the A␤42 level in cell-based assays) and later proved to have very poor brain penetrance. 6, 7 Despite having less than stellar pharmacodynamic and pharmacokinetic properties, a large phase 3 clinical trial involving more than 1600 mildly affected patients with AD was conducted using the NSAID-like compound R-flurbiprofen (Tarenflurbil; sponsored by Myriad Genetics, Inc). Unfortunately, this study failed to show any clinical benefit. 7 More recently, a potent series of compounds referred to as the non-NSAID-like or non-carboxylic acidcontaining ␥-secretase modulators (GSMs), harboring a completely different chemical scaffold from that of NSAIDs, have received considerable attention from pharmaceutical companies, biotechnology concerns, and academic laboratories. Within the last 18 months, more than 60 new patent applications have been published on slight variations of GSM chemical scaffolds highly similar to those originally reported by members of our team. 8 This may seem surprising given the recent failures of the GSI semagacestat and Tarenflurbil. However, those 2 compounds had the limitations mentioned earlier. Although GSIs and GSMs target the ␥-secretase enzyme complex, they appear to have distinct mechanisms of action as measured by their effects on the levels of the various A␤ peptide variants and C-terminal fragments such as C99. 3, 8 Unlike the GSIs, some these nonacidic GSMs (a series of diarylaminothiazoles) were found to be capable of potently inhibiting A␤42 production in vitro (cell-based halfmaximal inhibitory concentrations in the low nanomolar range) and in vivo. 8 At slightly higher concentrations, they reduce A␤40 levels only moderately while concomitantly increasing the levels of the shorter A␤38 and A␤37 peptide variants (Figure 2) . 8 Moreover, one of these nonacidic diarylaminothiazolecontaining GSMs was shown to markedly reduce A␤ deposition in a transgenic mouse model of AD following long-term daily administration for 29 consecutive weeks and did not show adverse effects that are commonly associated with long-term administration of GSIs in rodents such as goblet cell hyperplasia. 8 Potent GSMs that can selectively decrease the production of A␤42 will need to be rigorously tested during translation to clinical trials. The failure of R-flurbiprofen (Tarenflurbil) in the phase 3 trial highlights a critical first step: the need to demonstrate that a GSM engages its target and selectively lowers the A␤42 level in the brain in humans. This can be exam- D) . The graphs represent shifts in the different forms of ␤-amyloid (A␤) that result from processing by normal (wild-type) ␥-secretase, mutations in the presenilin component of ␥-secretase that result in EOFAD, and the effects of treatment with GSIs or GSMs. The heights (ordinate) and lengths (abscissa) of each A␤ peptide variant correspond to the relative abundance and the number of amino acids, respectively. The GSMs elicit a unique bidirectional biomarker profile with respect to their effects on A␤ peptide variants (decreasing A␤42 and A␤40 levels, while increasing A␤38 and A␤37 levels). AU indicates arbitrary units; CTFs, C-terminal fragments.
ined by pharmacokinetic and pharmacodynamic studies that analyze cerebrospinal fluid and plasma. Serial sampling of cerebrospinal fluid via an indwelling lumbar catheter may help to define the precise time course and selectivity of inhibition of A␤42 production and facilitate dose selection. These studies can also analyze other forms of A␤ such as A␤38, which, based on transgenic mouse studies, may increase in response to a potent GSM. 8 The studies can address the question of whether there is a rebound increase in A␤ production when drug levels fall-a problem previously cited with GSIs. 9 In planning clinical trials to test a potent GSM in relation to AD, several key issues need to be considered. It is unknown how much the A␤42 level needs to be lowered to have significant clinical benefits. Although dosing can be bracketed from phase 1 pharmacokinetic and pharmacodynamic studies, it is unclear whether reduction of A␤42 production by 25% (a moderate effect) or by 50% or higher (a large effect) is necessary to influence amyloid deposition and neuritic plaque dynamics in the brain. Monitoring plasma and cerebrospinal fluid during longterm dosing and the use of biomarkers such as amyloid imaging can provide tools to monitor these parameters. Biomarkers such as structural magnetic resonance imaging can supplement clinical assessment to provide insights into whether sustained lowering of the A␤42 level (and a concomitant increase in the A␤38 level) has benefits on brain structure and function. Toxic effects will need to be monitored carefully in view of the experience with semagacestat.
Although clinical trials have typically targeted people with symptomatic AD at a mild to moderate stage of dementia, this may not be the best approach for GSMs. First, the extent of brain amyloid burden does not correlate with the degree of cognitive impairment in AD. It is possible that a cascade of neurodegenerative processes eventually becomes independent of A␤ or amyloidrelated toxic effects and leads to progressive dementia in AD; decreasing A␤42 production may not be successful without simultaneously addressing other potential mechanisms of disease. Second, extensive structural neuronal pathology is already present in the hippocampus and other brain regions in people with mild to moderate AD, which limits the degree of recovery or improvement that may be achieved, even if treatment with GSMs leads to a dramatic reduction in amyloid burden. For these reasons, clinical trials of GSMs are likely to be more promising if conducted in people with very early symptomatic AD (eg, mild cognitive impairment).
With many potent GSMs currently in various stages of preclinical and clinical development, perhaps we should take a lesson from the history of compactin and prioritize limited proof-of-concept trial(s) with wellstudied EOFAD kindreds whose disease course, extending from preclinicalphasestoclinicaloutcomes,has been well mapped. Proof-of-principle studies have been proposed among presymptomaticormildlyaffectedcarriers of an extended Colombian family of more than 5000 members carrying a single PSEN1 genetic mutation who have been thoroughly studied for thepastfewdecades.Tomeetthisneed, GSMs must be capable of modulating a␥-secretase enzyme complex harboring EOFAD-linked mutations. Interestingly, unpublished experiments in 2 of our laboratories (R.E.T. and S.L.W.) suggest that these types of aminothiazole-containingGSMswork at least as well if not better against all 5ofthemutantpresenilin1-expressing cell lines tested so far compared with the cell lines expressing wild-type presenilin 1. Studies with carriers of familial AD-linked mutations could serve as important tests of therapeutic regimens targeting ␥-secretase and the amyloid cascade hypothesis. 
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